Is Corcept Therapeutics Incorporated (CORT) The Most Promising Growth Stock According to Analysts?

Core Insights - Corcept Therapeutics Incorporated (NASDAQ:CORT) is recognized as a promising growth stock by analysts [1] - The company plans to request a Type A meeting with the FDA to discuss the regulatory pathway for its drug relacorilant [4] Stock Performance and Analyst Ratings - William Guyer, Chief Development Officer at Corcept, sold 20,000 shares valued at $703,656 on January 6 [1] - H.C. Wainwright reduced the price target for Corcept from $145 to $90 while maintaining a 'Buy' rating, indicating a potential upside of nearly 141% from the current price [2] Regulatory Challenges - The FDA issued a Complete Response Letter regarding the new drug application for relacorilant, requiring additional confirmatory evidence despite acknowledging the pivotal GRACE trial [3] - H.C. Wainwright anticipates a three-year delay in the rollout of relacorilant, with a new expected launch in the first quarter of 2029 [4] Company Overview - Corcept Therapeutics is based in California and focuses on developing solutions for serious endocrinologic, oncologic, metabolic, and neurologic disorders [5]